Stocklore

Moderna, Inc. (MRNA)

Biotech & Health · US stock

Company overview

Moderna. A developer of mRNA-based vaccines and treatments. After its COVID-19 vaccine, it is developing varied pipelines in flu, cancer, and more.

What is the Biotech & Health sector?

Pharma, biotech, and medical devices. Driven by trial-result events.

Moderna, Inc. is classified under the Biotech & Health sector. See peers below.

Moderna, Inc. key financials

Based on SEC filings · latest quarter (TTM)

Tap a metric name to see its meaning in the glossary.

ETFs holding Moderna, Inc.

Per SEC N-PORT · 2026-03-31 · by weight · factual

XLVState Street(R) Health Care Select Sector SPDR(R) ETF
0.33%
RSPInvesco S&P 500 Equal Weight ETF
0.30%
VOOVANGUARD 500 INDEX FUND
0.03%
SPY
0.03%
IVViShares Core S&P 500 ETF
0.03%
VTIVANGUARD TOTAL STOCK MARKET INDEX FUND
0.03%
ITOTiShares Core S&P Total U.S. Stock Market ETF
0.03%

MRNA on Stocklore

  • Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
  • Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
  • 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
  • Sector-relative metrics — valuation and growth vs the Biotech & Health average
See full MRNA analysis →

Peers · Biotech & Health

MRNA FAQ

What is Moderna, Inc. (MRNA)?

Moderna. A developer of mRNA-based vaccines and treatments. After its COVID-19 vaccine, it is developing varied pipelines in flu, cancer, and more.

What sector is Moderna, Inc. in?

Moderna, Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.

What are Moderna, Inc.'s key financials?

Based on the latest quarter (TTM) from SEC filings: Revenue growth (YoY) -30.0%, Operating margin -356.8%, Net margin -143.6%, ROE -32.6%, Debt-to-equity 0.07x. Definitions and interpretation are available on Stocklore.

Where can I analyze Moderna, Inc. (MRNA) stock?

On Stocklore you can see MRNA's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.

Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, 45-day delay), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.

Not an investment adviser and not personalized investment advice; not a discretionary management service. No trade recommendations, no target prices, no execution or brokerage. We do not recommend or guarantee any purchase, sale, or returns. Investment decisions and their outcomes are your own.

Stocklore · CEO Lee Seung-jae · Business reg. no. 764-36-01607 · E-commerce permit 2026-Jeonju Wansan-0476 · Tel +82-70-7954-4939 · S120, Rm 302, 3F, 21 Jungsanjungang-ro, Wansan-gu, Jeonju, Jeonbuk, Korea